C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation(R), has reached an agreement with BeauBrain Healthcare that brings its breakthrough ...
Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果